Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $300 | $300 | $311 | $303 |
| Gross Profit | -$300 | -$300 | -$311 | -$303 |
| % Margin | – | – | – | – |
| R&D Expenses | $13,348 | $16,182 | $15,414 | $18,327 |
| G&A Expenses | $0 | $6,467 | $6,248 | $0 |
| SG&A Expenses | $6,039 | $6,467 | $6,248 | $6,324 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$300 | -$311 | $0 |
| Operating Expenses | $19,387 | $22,349 | $21,351 | $24,651 |
| Operating Income | -$19,687 | -$22,649 | -$21,662 | -$24,954 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,453 | $1,643 | $1,982 | $2,123 |
| Pre-Tax Income | -$18,234 | -$21,006 | -$19,680 | -$22,831 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18,234 | -$21,006 | -$19,680 | -$22,831 |
| % Margin | – | – | – | – |
| EPS | -0.47 | -0.55 | -0.51 | -0.6 |
| % Growth | 14.5% | -7.8% | 15% | – |
| EPS Diluted | -0.47 | -0.55 | -0.51 | -0.6 |
| Weighted Avg Shares Out | 38,560 | 38,462 | 38,350 | 38,242 |
| Weighted Avg Shares Out Dil | 38,560 | 38,462 | 38,350 | 38,242 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,506 | $1,730 | $1,996 | $2,363 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $300 | $300 | $311 | $303 |
| EBITDA | -$17,934 | -$20,706 | -$19,369 | -$22,528 |
| % Margin | – | – | – | – |